*Daisy Spark1,2, Juulke Castelijn1,2, Leonid Churilov3, Trang Pham2,4, Michelle Camerino2,4, Christopher J Langmead2,5,6, Gregory D Stewart2,5,6, Jess Nithianantharajah1,2 (1. The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia, 2. Phrenix Therapeutics, Parkville, Victoria, Australia, 3. Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia, 4. Australian Translational Medicinal Chemistry Facility, Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia, 5. Drug Discovery Biology, Neuroscience & Mental Health Therapeutic Program Area, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia, 6. Neuromedicines Discovery Centre, Monash University, Parkville, Victoria, Australia)
Session information
[CINP2024] Short Communications
CINP2024 » Short Communications
Short Communications 13
Schizophrenia and Pain - Preclinical
Sat. May 25, 2024 10:10 AM - 11:10 AM Room 8 (G405)
Chair: Rachel A. Hill (Monash University)
*Courtney Leigh Clarke1, Skylar Donovan1, SM Nageeb Hasan1, Francis Bambico1 (1. Memorial University of Newfoundland and Labrador)
*Rinako Tanaka1, Yue Liu1, Jingzhu Liao1, Akihiro Mouri2, Taku Nagai3, Toshitaka Nabeshima4, Kozo Kaibuchi5, Daiki Tachibana6, Yohei Kobayashi6, Norio Ozaki7, Hiroyuki Mizoguchi1, Kiyofumi Yamada1,8 (1. Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2. Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Toyoake, Japan, 3. Division of Behavioral Neuropharmacology, International Center for Brain Science (ICBS), Fujita Health University, Toyoake, Japan, 4. Laboratory of Health and Medical Science Innovation, Fujita Health University Graduate School of Health Sciences, Toyoake, Japan, 5. Division of Cell Biology, ICBS, Fujita Health University, Toyoake, Japan, 6. Pharmacology Research Unit, Sumitomo Pharma Co., Ltd., Osaka, Japan, 7. Pathophysiology of mental disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan, 8. ICBS, Fujita Health University, Toyoake, Japan)
*Martha Lopez Canul1, Vivienne Nguyen1, Antonio Inserra1, Ella Nield1, Hannah Billings1, Gabriella Gobbi1 (1. McGill University, Department of Psychiatry and Alan Edwards Centre for Research on Pain, Montréal, QC, Canada)
*Chihiro Nozaki1, Haruka Hosoki2, Andreas Zimmer3 (1. Global Center for Science and Engineering, Waseda University, Tokyo, Japan, 2. Graduate School of Advanced Science and Engineering, Waseda University, Tokyo, Japan, 3. Institute of Molecular Psychiatry, University of Bonn, Bonn, Germany)